Last study subjects of Peptonic Medical’s phase 2b study ready for enrolment
Stockholm, October 25th, 2016 – Peptonic Medical AB (publ) (“Peptonic” or “the Company”) – a company developing pharmaceuticals based on oxytocin – today announced the last study subjects of the ongoing phase 2b study now have been signed up to be enrolled. The last patient is expected to enter the study within a fortnight. In total, 160 study subjects are participating in the study, the objective of which is to investigate the effect of Peptonic Medical’s candidate drug Vagitocin® in the treatment of vaginal atrophy in post menopausal women. In this study, a glass syringe is used for